Lu Ning, Li Zhi-hui, Wang Guang-lu, Zhang Feng, Peng Xiao-yan
Beijing Tongren Ophthalmic Center, Capital University of Medical Science, Beijing 100730, China.
Zhonghua Yan Ke Za Zhi. 2004 Jan;40(1):20-5.
To test the effectiveness and safety of laser-induced chorioretinal venous anastomosis in the treatment of nonischemic central retinal vein occlusion (CRVO), and also the effectiveness of the preventative measures for complications associated with the treatment.
Laser-induced chorioretinal venous anastomosis was performed on 34 cases, 35 eyes with nonischemic CRVO. During the treatment, preventative measures for complications were taken as follows: (1) Patients with total retinal papillary nonperfusion area of less than 5 DA were selected to receive the treatment. (2) Treatment sites must be at least 3 PD away from the optic disc and 4 PD away from the macula. (3) At most 2 argon laser shots were attempted over each treatment site, to avoid severe laser damage. (4) Scattered argon laser photocoagulation was done over the drainage area of the vein distal to the treatment site, in order to prevent neovascular complications in case distal vein occlusion occur.
During the 3 approximately 12 months (average 6 months) follow-up, successful anastomosis formed in 28 eyes out of 35 eyes (80%) with a mean of 2.4 attempts to create an anastomosis in each eye. With successful anastomosis, retinal hemorrhage started to be absorbed gradually 2 weeks after the treatment, and almost entirely absorbed 1 approximately 2 months later. Retinal edema also alleviated. Visual acuity improved in 20 out of 28 eyes (71%), and remained unchanged in the rest of the patients with successful anastomosis. In comparison with the natural course of the disease, our treatment has improved both the visual prognosis and the retinal damage caused by the disease. No serious complications occurred in these patients with successful anastomosis. Anastomosis failed to form in 7 cases (7 eyes), among which, 2 eyes developed serious neovascular complications.
CRVA treatment is effective in the treatment of non-ischaemic CRVO. With proper preventative measures for complications associated with the treatment, the safety of the treatment can be increased prominently, but serious neovascular complications was not entirely prevented.
探讨激光诱导脉络膜视网膜静脉吻合术治疗非缺血性中央视网膜静脉阻塞(CRVO)的有效性和安全性,以及治疗相关并发症预防措施的有效性。
对34例(35只眼)非缺血性CRVO患者行激光诱导脉络膜视网膜静脉吻合术。治疗过程中采取如下并发症预防措施:(1)选择视网膜视乳头总无灌注区小于5 DA的患者接受治疗。(2)治疗部位必须距视盘至少3 PD,距黄斑至少4 PD。(3)每个治疗部位最多尝试2次氩激光照射,以避免严重激光损伤。(4)在治疗部位远端静脉引流区行氩激光散在光凝,以防远端静脉阻塞时发生新生血管并发症。
在约3至12个月(平均6个月)的随访期间,35只眼中28只眼(80%)形成了成功的吻合,每只眼平均进行2.4次吻合尝试。成功吻合后,视网膜出血在治疗后2周开始逐渐吸收,1至2个月后几乎完全吸收。视网膜水肿也有所减轻。28只眼中20只眼(71%)视力提高,其余成功吻合的患者视力保持不变。与疾病自然病程相比,我们的治疗改善了视力预后以及疾病所致的视网膜损害。这些成功吻合的患者未发生严重并发症。7例(7只眼)吻合未成功,其中2只眼发生了严重的新生血管并发症。
激光诱导脉络膜视网膜静脉吻合术治疗非缺血性CRVO有效。采取适当的治疗相关并发症预防措施可显著提高治疗安全性,但不能完全预防严重的新生血管并发症。